- Home
- SPRY
as 03-28-2025 4:00pm EST
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.2B | IPO Year: | N/A |
| Target Price: | $28.75 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.55 - $18.51 | Next Earning Date: | 03-20-2025 |
| Revenue: | $89,149,000 | Revenue Growth: | 297063.34% |
| Revenue Growth (this year): | 41.49% | Revenue Growth (next year): | 80.23% |
Stock Insider Trading Activity of ARS Pharmaceuticals Inc. (SPRY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Karas Eric | SPRY | Chief Commercial Officer | Mar 20 '25 | Sell | $14.00 | 10,000 | $140,000.00 | 7,696 | |
| Shawver Laura | SPRY | Director | Mar 5 '25 | Sell | $11.11 | 50,000 | $560,445.76 | 210,346 | |
| Shawver Laura | SPRY | Director | Feb 3 '25 | Sell | $12.31 | 50,000 | $615,565.00 | 210,346 | |
| Shawver Laura | SPRY | Director | Jan 6 '25 | Sell | $11.10 | 50,000 | $555,065.00 | 210,346 |
Latest ARS Pharmaceuticals Inc. News
SPRY Breaking Stock News: Dive into SPRY Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This Year
TipRanks
8 days ago
Accenture reports Q2 beat, Apple TV+ losing $1B annually: Morning Buzz
GuruFocus.com
8 days ago
ARS Pharmaceuticals Inc (SPRY) Q4 2024 Earnings Report Preview: What To Expect
Simply Wall St.
8 days ago
ARS Pharmaceuticals Full Year 2024 Earnings: Beats Expectations
GuruFocus.com
8 days ago
ARS Pharmaceuticals Inc (SPRY) Q4 2024 Earnings Call Highlights: Strong Financial Position and ...
Thomson Reuters StreetEvents
8 days ago
Q4 2024 ARS Pharmaceuticals Inc Earnings Call
Investor's Business Daily
8 days ago
ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why.
MT Newswires
9 days ago
Sector Update: Health Care Stocks Decline Pre-Bell Thursday
Compare SPRY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SPRY ARS Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.